(PharmaNewsWire.Com, January 10, 2018 ) Crohns disease (CD) is a form of inflammatory bowel disease (IBD), which is comprised of two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease (CD) and ulcerative colitis (UC). In CD, chronic inflammation may affect any part of the gastrointestinal (GI) tract from the mouth to the anal area; however, CD occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The pathophysiology of CD is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission.
Publisher estimates the 2016 sales for the COPD market at approximately $9.2 billion across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. Over the course of the 10-year forecast period, the CD market is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.8% across the 7MM. Each of the 7MM are anticipated to grow, recording CAGRs of 4.9%, 1.3%, and 3.6% across the US, 5EU, and Japan, respectively. At the end of 2026, the US will account for 87.2% of sales across the 7MM, while the 5EU and Japan, will account for around 11.3% and 1.4% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of CD in the region, as well as the high annual cost of therapy (ACOT) of J&J's Stelara and the anticipated ACOT of AbbVie's risankizumab in the US market.
Report Scope: -Overview of CD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies. -Topline CD market revenue from 2016-2026. ACOT and major pipeline product sales in this forecast period are included. -Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CD therapeutics sales in the 7MM. -Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. -Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy: The report will enable you to- -Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. -Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market. -Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CD therapeutics market in the future. -Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. -Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. -Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
